Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rishi Puri

Interventional Cardiology Cleveland, OH Medical Doctor

NPI 1821570128 CMS profile 4337902

9500 Euclid Ave # J2-208, Cleveland, OH 44195

Open in the dashboard

General payments

$184,821

381 records reported · program years 2019–2025

Research payments

$8,719

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$359,348 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Rishi Puri of Cleveland, OH is reported in the CMS Open Payments database as having received $184,821 across 381 general payments and $8,719 in research payments paid to them. Separately, studies naming them as principal investigator received $359,348 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,792 76
2024 General $64,514 67
2023 General $23,648 75
2023 Research $656 2
2022 General $39,265 68
2022 Research $938 3
2021 General $16,976 42
2021 Research $7,125 3
2020 General $6,212 14
2019 General $8,414 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rishi Puri
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rishi Puri were reported at $25,792. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rishi Puri Interventional Cardiology median Middle half National median
2019 $8,414 $1,097 $329–$3,048 $163
2020 $6,212 $473 $161–$1,480 $114
2021 $16,976 $677 $233–$1,827 $132
2022 $39,265 $978 $333–$2,724 $149
2023 $23,648 $1,136 $382–$2,986 $160
2024 $64,514 $1,181 $395–$3,326 $164
2025 $25,792 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $76,110 189 payments
  2. Abbott Laboratories $66,171 88 payments
  3. Centerline Biomedical Inc. $15,263 3 payments
  4. Medtronic Vascular, Inc. $12,882 32 payments
  5. Shockwave Medical, Inc $7,597 8 payments
  6. Boston Scientific Corporation $2,983 26 payments
  7. Ancora Heart, Inc. $2,130 9 payments
  8. Ge Healthcare $571 8 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $398 7 payments
  10. Edwards Lifesciences Corporation $280 4 payments
  11. Other $437 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $126,678 27 payments
  2. Travel and Lodging $27,756 127 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,969 14 payments
  4. Food and Beverage $13,637 210 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,500 2 payments
  6. Long term medical supply or device loan $282 1 payment
Products named General payments · program years 2019–2025
  1. NAVITOR Vascular $48,096 32 payments
  2. COREVALVE EVOLUT R $44,120 90 payments
  3. CoreValve Evolut Transcatheter Valve Systems $12,007 29 payments
  4. Vascular Lithotripsy $7,597 8 payments
  5. NAVITOR Structural Heart $7,055 14 payments
  6. CoreValve Evolut Transcatheter Valve Systems $5,896 16 payments
  7. PORTICO $4,830 19 payments
  8. MITRACLIP $2,980 6 payments
  9. TRICLIP $2,677 12 payments
  10. AccuCinch $2,130 9 payments
  11. Other $6,704 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $8,719 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,484

Median for Interventional Cardiology: 2,236

Drug cost

$492,328

Median for Interventional Cardiology: $380,412

Branded share of claims

44.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 101 $134,012
Entresto Sacubitril/Valsartan Brand 75 $96,196
Eliquis Apixaban Brand 80 $80,924
Farxiga Dapagliflozin Propanediol Brand 56 $65,788
Repatha Sureclick Evolocumab Brand 81 $50,854
Repatha Pushtronex Evolocumab Brand 49 $35,668
Brilinta Ticagrelor Brand 20 $11,664
Prasugrel Hcl Generic 25 $2,691
Ranolazine Er Ranolazine Brand 23 $2,441
Rosuvastatin Calcium Generic 150 $2,360

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$128,018

Medicare's payments for the services billed

Medicare patients

405

Average age 78

Services billed

851

183 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Arthritis 54%
Atrial fibrillation 53%
Chronic kidney disease 46%
Diabetes 39%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

389 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record